FY2023 · ended Dec 31, 2023 · Revenue $2.00M · Filed Mar 12, 2025
Sagimet Biosciences Inc. (SGMT) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $257.6 million in cash and investments and $1.9 million in total debt.
Revenue
$2.00M
Net income
$-51.04M
-12.0% vs prior year
Operating cash flow (TTM)
$-41.72M
+23.1% vs year-ago TTM
Free cash flow
—
EPS
$-1.58
-9.0% vs prior year
Dividend per share
None
Shares outstanding
0
Net cash
$255.62M
as of Jun 30, 2026
Operating margin
-1537.0%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SGMT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1400118
- Former names
- 3-V Biosciences, Inc. (until Feb 25, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | — | — | $2.0M |
| Operating income | -$56.9M | -$54.5M | -$30.7M |
| Net income | -$51.0M | -$45.6M | -$27.9M |
| Diluted EPS | -$1.58 | -$1.45 | -$2.66 |
| Operating cash flow | -$45.6M | -$42.4M | -$23.8M |
| Total assets | $116.5M | $160.3M | $96.7M |
| Total liabilities | — | — | $5.7M |
| Stockholders' equity | $111.4M | $155.8M | $91.1M |
| Cash and investments | $113.1M | $158.7M | $94.9M |
| Total debt | $78,000 | $78,000 | $65,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 1, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
All 262 Sagimet Biosciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.